Sodium-glucose cotransporter 2 inhibitors in the treatment of refractory hypomagnesemia
- 20 February 2024
- journal article
- letter
- Published by Elsevier in Kidney International
- Vol. 105 (3) , 638
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetesKidney International, 2023
- SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 PatientsKidney Medicine, 2020
- Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trialsDiabetologia, 2016
- When EGF is offside, magnesium is wastedJournal of Clinical Investigation, 2007